Morgan Stanley raised the firm’s price target on Guardant Health (GH) to $52 from $42 and keeps an Overweight rating on the shares. Q4 revenue of $201.8M was up 30% year-over-year and above the preliminary view of about $200M, driven by strong clinical revenue on the back of average selling price and reimbursement tailwinds, the analyst tells investors. The company’s 2025 revenue guidance came in “modestly above” the Street view, with room for upside, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $50 from $34 at Piper Sandler
- Guardant Health price target raised to $52 from $47 at Scotiabank
- Guardant Health price target raised to $60 from $42 at Canaccord
- Guardant Health: Positioned for Growth with Shield CRC and Strategic Market Advantages
- Guardant Health Projects Strong Growth Amid Challenges
Questions or Comments about the article? Write to editor@tipranks.com